1. Home
  2. AGCC vs RVPH Comparison

AGCC vs RVPH Comparison

Compare AGCC & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGCC

Agencia Comercial Spirits Ltd Class A Ordinary Shares

N/A

Current Price

$12.64

Market Cap

87.9M

ML Signal

N/A

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.62

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGCC
RVPH
Founded
2020
2006
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.9M
71.0M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
AGCC
RVPH
Price
$12.64
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.33
AVG Volume (30 Days)
130.4K
3.7M
Earning Date
12-19-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$2,537,743.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$158.48
N/A
Revenue Growth
186.00
N/A
52 Week Low
$3.66
$0.25
52 Week High
$13.78
$4.28

Technical Indicators

Market Signals
Indicator
AGCC
RVPH
Relative Strength Index (RSI) N/A 58.21
Support Level N/A $0.55
Resistance Level N/A $0.65
Average True Range (ATR) 0.00 0.05
MACD 0.00 0.01
Stochastic Oscillator 0.00 86.36

Price Performance

Historical Comparison
AGCC
RVPH

About AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares

Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: